Wegovy maker sues Hims & Hers after company launches $49 weight-loss pill

Novo Nordisk filed a federal patent-infringement suit on Feb. 9 in Delaware against telehealth provider Hims & Hers after the latter announced a compounded version of Novo’s semaglutide weight-loss pill (Wegovy) at an introductory $49/month; Hims halted sales on Feb. 7 following FDA warnings. Novo alleges unlawful mass marketing of unapproved knock-offs and injectable copies that threaten patient safety, while the FDA has moved to restrict compounded GLP-1 ingredients and set enforcement deadlines after declaring a prior semaglutide shortage over. The dispute raises legal and regulatory risk for Hims & Hers and other compounding pharmacies and could affect competitive dynamics in the high-demand semaglutide market.

Analysis

Market structure: Novo Nordisk (NVO) is the clear incumbent beneficiary — successful enforcement preserves pricing power and prevents a <$50/month commoditization of semaglutide; expect modest positive EPS tailwind (low-single-digit % revenue protection) if compounding is curtailed. Hims & Hers (TDAY) is an immediate loser: revenue and customer-acquisition upside from a $49 pill is extinguished and regulatory/legal costs will pressure margins and raise equity volatility.

Risk assessment: Near-term (days–weeks) tail risk is regulatory headline volatility and a preliminary injunction that could freeze Hims’ activities; medium-term (1–6 months) risk is a court decision or FDA guidance favoring either side; long-term (12+ months) risk includes precedent that could either deter future compounding (good for NVO) or limit exclusivity (bad for NVO). Hidden dependencies include API supply controls, state compounding statutes, and secondary litigation from other telehealth providers.

Trade implications: Primary trades are long NVO and short/hedge TDAY — asymmetric risk: NVO upside capped by competing GLP-1 entrants, TDAY downside amplified by enforcement and litigation. Options implied vol should rise on TDAY; use limited-loss structures (put spreads) rather than naked shorts; consider pair trades to isolate regulatory vs. demand exposure.

Contrarian angles: Consensus underprices legal timelines — courts can take months, giving HIMS time to pivot or monetize a settlement; conversely, if FDA tightens API controls within 30–90 days, HIMS downside could be front-loaded. Historical parallel: pharma wins major suits >70% when patent and FDA approval history are strong, suggesting odds favor NVO but not certainty.

Key Decisions for Investors

• Establish a 2–3% long position in NVO equity within 7 trading days to play IP protection and pricing power; trim at +15–25% or on a court ruling adverse to Hims, add if FDA issues explicit ingredient-restriction guidance within 30–90 days.
• Initiate a 1–1.5% short position in TDAY (or equivalent CDS if available) immediately; tighten stop to 10% loss and target 30–50% downside if FDA enforcement actions or a preliminary injunction are announced within 30 days.
• Implement a 90–180 day options hedge on TDAY: buy 90-day put spread (e.g., 25–35% OTM) sized to limit max loss to 0.5% of portfolio while capturing regulatory-driven vol — roll/close on an adverse court temporary restraining order or at 50% of max spread value.
• Pair trade: long NVO (2%) vs short TDAY (1%) to capture regulatory arbitrage; rebalance after 1st court hearing or FDA guidance (likely within 30–90 days) and take profits if spread narrows by 50% or widens by 100%.
• Reduce exposure by 1–2% to small-cap telehealth/digital-health ETFs for next 60–120 days; regulatory spillover risk suggests reallocate to large-cap pharma and staples until headlines settle.